MUC2 and neoplasm: We hypothesize that the expression of PD-L1, GLUT-1, e-cadherin, MUC2, and CDX2, in addition to the MMR proteins in tumor samples, can help create an IHC biomarker panel that is able to discern patient prognosis in early-stage colon cancer.